论文部分内容阅读
目的 :评价诺和灵 3 0 R治疗糖尿病的临床疗效。方法 :对近 2年收治的 60例糖尿病患者随机采用诺和灵 3 0 R(生物合成人胰岛素 预混型 )及短效型正规胰岛素治疗各 3 0例 ,观察其血糖谱变化。结果 :该药在控制血糖方面 ,日用量较正规胰岛素减少 2 7.19%± 7.2 5 % ;在控制空腹血糖及早、中、晚餐后血糖上 ,两组均较治疗前明显下降 ( P <0 .0 1) ,其中诺和灵组空腹血糖较正规胰岛素组下降明显 ( P <0 .0 5 ) ,而三餐后血糖下降两组差异不显著。结论 :诺和灵 3 0 R在治疗糖尿病控制血糖方面效能优于正规胰岛素
Objective: To evaluate the clinical efficacy of Novolin 3 0 R in the treatment of diabetes mellitus. Methods: 60 cases of diabetic patients admitted to the past two years were randomized to receive Noropenem 30R (biosynthetic human insulin pre-mixed type) and short-acting regular insulin (30 cases each), and their blood glucose profiles were observed. Results: In the control of blood glucose, the daily dosage of this medicine was reduced by 21.19% ± 7.25% compared with that of regular insulin. On the control of fasting blood glucose, the blood glucose of the two groups were significantly lower than before treatment (P <0. 0 1). The fasting blood glucose of noradrenaline group was significantly lower than that of regular insulin group (P <0.05), but no significant difference was found between the two groups after three meals. Conclusion: Novolin 3 0 R is superior to regular insulin in controlling diabetes for blood sugar